ALX Oncology More Than Doubles In Pre-market After Positive Interim Phase 2 Data From ASPEN-06 Trial

Shares of ALX Oncology Holdings Inc. (ALXO) were trading up over 114 percent on Tuesday after the company reported positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial of Evorpacept for Cancer.

from RTT - Before the Bell https://ift.tt/iG9rhaN
via IFTTT